The Novavax vaccine is created using more traditional protein-based technology for vaccine development, unlike the other vaccines currently available in the United States (the Pfizer and Moderna mRNA vaccines and viral-vector Johnson & Johnson vaccine).
The Novavax vaccine uses a combination of purified coronavirus spike proteins and an immune-boosting stimulant called an adjuvant (common in many vaccines) to strengthen the body’s immune response against COVID-19. Novavax has already been authorized in more than 40 countries and has been granted emergency authorization from the European Union and the World Health Organization.
Updated June 29, 2022